Answers are grounded in this paper and cite their sources.
Obesity has reached epidemic proportions globally, with projections indicating that by 2050, nearly 3.8 billion adults will be overweight or obese. Despite the critical need for effective interventions, current obesity treatments ranging from lifestyle changes to bariatric surgery are often limited in efficacy or suitability. Pharmacotherapy is increasingly utilized for individuals with significant obesity or related comorbidities. However, some anti-obesity medications have been linked to ocular complications such as non-arteritic anterior ischemic optic neuropathy and diabetic retinopathy progression. This review analyzes currently approved anti-obesity medications, emphasizing their potential ocular adverse effects and the underlying mechanisms by which these occur. A comprehensive literature search identified the historical evolution, classification, and spectrum of ocular effects associated with these agents. The findings underscore the importance of evaluating both the risks and benefits of anti-obesity pharmacotherapy and highlight the need for vigilant clinical assessment of ocular health in patients undergoing such treatments.
No takes yet. Share an insight, caveat, or question.
Khullar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: